X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Rytstat
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023
Details:
Oxemia (desidustat), a HIF-PF inhibitor met its primary endpoints for haemoglobin improvement in DREAM-D and DREAM-ND Phase III clinical trials and showed good safety profile, downregulation of hepcidin, improved iron mobilization and LDL-C reduction in CKD patients.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Oxemia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
The study demonstrated the noninferiority of Desidustat compared to Epoetin in the treatment of anemia in patients with CKD who were on dialysis. Desidustat is also under clinical trials for Cancer Chemotherapy Induced Anemia (CIA).
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
The Phase 2(b) results of this study revealed that Desidustat treatment led to increased red blood cell production and improved oxygen delivery to tissues.
Lead Product(s): Desidustat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Oxemia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: China Medical System
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
